Ripretinib (gastrointestinal stromal tumor (GIST), ≥ 3 previous therapies)

Subject:

• Active Substance: Ripretinib
• Name: Qinlock^®
• Therapeutic area: Gastrointestinal stromal tumor (GIST)
• Pharmaceutical company: Deciphera Pharmaceuticals (Netherlands) B.V.

Time table:

• Start: 01.01.2022
• Final decision by G-BA: 16.06.2022

Final decision:

• Hint for a major additional benefit